HIMS Stock Overview
Operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 6/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Community Narratives
Narratives bring a range of perspectives from our community.
Hims & Hers are taking grip on Telemedicine
Hims & Hers Health, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$14.73 |
| 52 Week High | US$25.74 |
| 52 Week Low | US$5.65 |
| Beta | 1.07 |
| 11 Month Change | -16.21% |
| 3 Month Change | -28.11% |
| 1 Year Change | 115.04% |
| 33 Year Change | 79.42% |
| 5 Year Change | n/a |
| Change since IPO | 50.31% |
Recent News & Updates
Hims & Hers Health Post Q2 Earnings - Compounded GLP-1 Ploy Faces New Threats (Rating Downgrade)
Aug 27Hims & Hers: Digesting Q2 2024 Earnings, Shares Still Undervalued, Rating Downgrade
Aug 20Hims & Hers Health, Inc.'s (NYSE:HIMS) Share Price Is Still Matching Investor Opinion Despite 27% Slump
Aug 11
Hims & Hers Health: Buy The Dip, With Or Without The GLP-1 Shortage
Aug 07Recent updates
Hims & Hers Health Post Q2 Earnings - Compounded GLP-1 Ploy Faces New Threats (Rating Downgrade)
Aug 27Hims & Hers: Digesting Q2 2024 Earnings, Shares Still Undervalued, Rating Downgrade
Aug 20Hims & Hers Health, Inc.'s (NYSE:HIMS) Share Price Is Still Matching Investor Opinion Despite 27% Slump
Aug 11Hims & Hers Health: Buy The Dip, With Or Without The GLP-1 Shortage
Aug 07Hims & Hers: The Thesis Goes Far Beyond GLP-1
Jul 18Hims & Hers: Buy The Dip To Catch The Next Rip
Jun 24Why Investors Shouldn't Be Surprised By Hims & Hers Health, Inc.'s (NYSE:HIMS) 70% Share Price Surge
Jun 19Hims & Hers: The Undervalued Gem Poised For Growth
Jun 18Beyond The Marketing Machine: Why Hims & Hers Stock Might Be Vulnerable
Jun 10Hims & Hers Health, Inc.'s (NYSE:HIMS) CEO Compensation Is Looking A Bit Stretched At The Moment
May 31Hims & Hers: Soaring On Access To Compounded GLP-1 Drugs, Further Volatility Ahead
May 21Hims & Hers Health: An Unforced Error
May 06Hims & Hers Health, Inc. (NYSE:HIMS) Stocks Pounded By 27% But Not Lagging Industry On Growth Or Pricing
May 04Hims & Hers Health: Becoming A Market Leader Within The Growing Digital Health Industry
Apr 24Hims & Hers Health: Strong Prospects But Weak Business Model Consolidation
Apr 05Hims & Hers: 5 Reasons Why This Is A Phenomenal Long-Term Growth Stock
Mar 21Pills Pay The Bills: Mini Deep Dive On Hims & Hers Health
Mar 12Investors Appear Satisfied With Hims & Hers Health, Inc.'s (NYSE:HIMS) Prospects As Shares Rocket 49%
Feb 28Hims & Hers: Turning The Profitability Corner And Returning 28%
Feb 25Hims & Hers Health: No Clear Moat Besides First Mover Advantage
Jan 23Hims & Hers Health: Unleashing Macro Momentum - Investing In Growth At A Higher Multiple
Jan 10Investors Still Waiting For A Pull Back In Hims & Hers Health, Inc. (NYSE:HIMS)
Jan 07Hims & Hers Health Q3: The Cheapest Growth Stock Around
Dec 14Hims & Hers Health: What Would The Author Of 100 Baggers Say?
Nov 30Hims & Hers: The Most Undervalued Small Cap Stock I See
Nov 08Hims & Hers: A Promising Company With Resolvable Challenges
Nov 02Hims & Hers: Specialization Is The Secret To Great Growth
Oct 25Hims & Hers Health: Can't Get Much Better
Sep 25The Market Is Wrong On Hims & Hers Health
Sep 18Hims & Hers: The Current Weakness Creates A Buying Opportunity
Aug 15Hims & Hers Health: Giving Investors Another Bite At The Apple
Aug 01Hims & Hers Health, Inc.'s (NYSE:HIMS) Price In Tune With Revenues
Jul 21Hims & Hers Health: Expect Strong EBITDA Growth As Revenue Growth Remains Strong
Jul 13Hims & Hers Health: Double-Edged Sword
Jul 02Hims & Hers: More Transparency Could Help The Stock
Jun 09Shareholder Returns
| HIMS | US Healthcare | US Market | |
|---|---|---|---|
| 7D | -12.0% | 0.8% | 0.06% |
| 1Y | 115.0% | 17.5% | 22.6% |
Return vs Industry: HIMS exceeded the US Healthcare industry which returned 17.5% over the past year.
Return vs Market: HIMS exceeded the US Market which returned 22.6% over the past year.
Price Volatility
| HIMS volatility | |
|---|---|
| HIMS Average Weekly Movement | 9.8% |
| Healthcare Industry Average Movement | 6.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.0% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: HIMS's share price has been volatile over the past 3 months.
Volatility Over Time: HIMS's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 1,046 | Andrew Dudum | www.forhims.com |
Hims & Hers Health, Inc. operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supplement products primarily focusing on general wellness, sexual health and wellness, skincare, and hair care.
Hims & Hers Health, Inc. Fundamentals Summary
| HIMS fundamental statistics | |
|---|---|
| Market cap | US$3.20b |
| Earnings (TTM) | US$18.10m |
| Revenue (TTM) | US$1.07b |
176.6x
P/E Ratio3.0x
P/S RatioIs HIMS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HIMS income statement (TTM) | |
|---|---|
| Revenue | US$1.07b |
| Cost of Revenue | US$190.06m |
| Gross Profit | US$877.07m |
| Other Expenses | US$858.97m |
| Earnings | US$18.10m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.083 |
| Gross Margin | 82.19% |
| Net Profit Margin | 1.70% |
| Debt/Equity Ratio | 0% |
How did HIMS perform over the long term?
See historical performance and comparison